Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
127 hedge funds and large institutions have $454M invested in Kezar Life Sciences in 2022 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 24 closing their positions.
402% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $6.72M
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
12.39% more ownership
Funds ownership: 78.49% → 90.88% (+12%)
3% more funds holding
Funds holding: 123 → 127 (+4)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
38% less capital invested
Capital invested by funds: $734M → $454M (-$280M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$26.5M |
| 2 |
Millennium Management
New York
|
+$16.1M |
| 3 |
CA
CHI Advisors
New York
|
+$13.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$12.8M |
| 5 |
O
OrbiMed
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$14.4M |
| 2 |
Holocene Advisors
New York
|
-$13.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$9.89M |
KZR Hedge Fund Activity: Q2 2022 in Review
127 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2022, worth a combined $454M — down 38% from $734M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new KZR positions and 24 closed out — a net gain of 6 holders — while 51 added to existing stakes and 34 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $26.5M. The largest seller was Bellevue Group, cutting an estimated $14.4M.
- 127 institutional investors held Kezar Life Sciences (KZR) as of Q2 2022, up from 123 in Q1 2022.
- Funds reported $454M of Kezar Life Sciences stock for Q2 2022, down 38% quarter-over-quarter.
- 30 funds opened new Kezar Life Sciences positions in Q2 2022 and 24 closed out, a net change of +6 holders.
- The largest Kezar Life Sciences buyer in Q2 2022 was Suvretta Capital Management, an estimated $26.5M added.
- The largest Kezar Life Sciences seller in Q2 2022 was Bellevue Group, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2022.